AbCellera Biologics Inc vs Figs Inc — how do they compare? AbCellera Biologics Inc trades at $9.24 (market cap $2.99B), while Figs Inc trades at $14.27 (market cap $2.37B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | FIGS | |
|---|---|---|
Market Cap | $2.99B | $2.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $17.12 |
52-Week Low | $2.78 | $6.57 |
Enterprise Value | $2.58B | $2.13B |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
FIGS stock trades at $14.39, up 0.91% today, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with 28.8% revenue growth, and raised its full-year outlook. Valuation remains elevated with a P/E of 43.24 and P/S of 3.83, while profitability improved with a net income margin of 8.72% in 2025.
The outlook is positive given accelerating revenue growth and margin expansion, but the rich valuation poses a risk if execution falters. Analyst consensus is bullish with a $19.50 price target, though high RSI readings suggest near-term overbought conditions. Key risks include second-half execution challenges and competitive pressures in healthcare apparel.
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →